Geneva, Oct. 15 -- International Clinical Trials Registry received information related to the study (ChiCTR2600134053) titled 'Efficacy, Safety and Annual Drug Retention Rate of Reminton, an Infliximab Biosimilar, for Crohn's Disease: A Retrospective Analysis' on Oct. 10.

Study Type: Observational study

Study Design: Cohort study

Primary Sponsor: The First Affiliated Hospital of Xiamen University

Condition: Crohn's disease

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2026-10-16

Target Sample Size: Crohn's disease Leiting-treated group:118;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=345841

Disclaimer: Curated by HT Syndication....